Michel Sadelain, MD, PhD

Michel Sadelain, MD, PhD
Memorial Sloan Kettering Cancer Center

Year Funded:

Leukemia / Lymphoma

Targeting leukemia and lymphoma with CD19-specific T cells co-stimulated by CD28 and lnterleukln-15

This clinical translational proposal aimed to assess the therapeutic potential of genetically targeted T cells in the treatment of leukemia and lymphoma. The introduction of genes that code for tumor-specific receptors into T lymphocytes, which are cells of the immune system that mediate tumor elimination, was a novel approach to cancer therapy.

Dr. Sadelain demonstrated that human peripheral blood T cells could be effectively redirected to recognize the CO19 antigen and eradicate established, systemic human B cell tumors borne by immunodeficient mice, This was the first publication showing that genetically modified human T cells can induce durable remissions in an in vivo setting.

Importantly, he found that T cell stimulation with the cytokine lnterleukln-15, but not the widely used lnterteukin-2, is critical for sustaining the therapeutic activity of infused CO19-spedflc T cells. Having examined the nature of the signals required by the T cells for their own survival and sustained functionality, Dr. Sadelain designed improved antigen receptors that provide both activating and co-stimulatory signals to the tumor-targeted T cell.

The specific alms of the 2004 application included:

  1. Demonstrating the therapeutic efficacy of leukemia and lymphoma patients’ cos+ T lymphocytes transduced with the 19/28z receptor In tumor-bearing mice
  2. Establishing clinical conditions for patient T cell purification, transduction and expansion, for review by the FDA
  3. Investigating, in a phase I clinical trial In patients with relapsed B cell leukemias, the safety, persistence and therapeutic efficacy of autologous IL15-actlvated CDS+ T cells that express 19/2Sz

Academic Profile

Read profile

Michel Sadelain, MD, PhD
Stephen and Barbara Friedman Chair
Director, Center for Cell Engineering
Memorial Sloan Kettering Cancer Center
1275 York Avenue
New York, NY 10065